We extend our deepest gratitude to the Members of Congress who fought to preserve Duchenne funding and to the Department of Defense for recognizing the importance of this research.
Applications submitted to the FY25 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that focus on the primary pathology of DMD. Therapies that will be efficacious across the lifespan, including infants, toddlers, and nonambulatory individuals are strongly encouraged.
Funds allocated for Duchenne through the CDMRP will support:
- Innovative Research: Advancing promising scientific discoveries despite an increasingly constrained funding environment.
- Translational Studies: Ensuring that research moves efficiently from the lab to clinical applications, even as resources grow scarcer.
- New Technologies and Biomarker Development: Supporting improved diagnostic tools and trial methodologies amid growing funding uncertainty.
- Follow Us -
